Solriamfetol Improves Cognitive Impairment Associated With OSA, EDS

Solriamfetol improved objective and subjective measures of cognitive function in patients with cognitive impairment associated with obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS), according to a poster presentation at Psych Congress.

The double-blind, randomized controlled crossover trial included 59 patients who received 150 mg of daily solriamfetol for 2 weeks, and placebo for 2 weeks, with a 1-week washout. The primary endpoint was change from baseline in average post-dose scores on a version of the Digit Symbol Substitution Test in the Repeatable Battery for the Assessment of Neuropsychological Status (DSST RBANS).

Related: Which sleep disturbance is most strongly predictive of MDD recurrence?

“Solriamfetol improved DSST RBANS scores compared to placebo (6.49 vs. 4.75, p=0.009), with an effect size (Cohen’s d) of 0.36,” reported first author Eileen Leary, PhD, of Axsome Therapeutics, and coauthors. 

Solriamfetol also significantly improved several key secondary endpoints — specifically, scores on the British Columbia Cognitive Complaints Inventory, Patient Global Impression of Severity, and the Epworth Sleepiness Scale.

“The adverse events profile and high completion rate suggest solriamfetol was well tolerated,” researchers reported. “These findings support the use of solriamfetol to improve cognitive performance in patients with cognitive impairment associated with OSA and EDS.”

Axsome Therapeutics and Jazz Pharmaceuticals sponsored the study. 

Reference

Leary E, et al. Effects of solriamfetol on cognition in participants with cognitive impairment associated with excessive daytime sleepiness in obstructive sleep apnea: SHARP study results. Poster presented at Psych Congress; September 6-10, 2023; Nashville, Tennessee.